Another step for psychedelics . . . and other research
British medical journal August 20, 2026 T. Nolan
Tom Nolan reviews this week’s research
British medical journal
ISSN 1759-2151
4 papers in the library · 195 citations · publishing 2022-2026
Papers
Australia’s approval of MDMA and psilocybin for PTSD and depression is premature, say critics
British medical journal July 11, 2023 B. Nogrady 18 citations
The TGA attached conditions to their use: namely, that onlypsychiatristswhoare trainedandauthorised to prescribe MDMA and psilocybin can do so, that a human research ethics committeemust approve each patient case, and that the treatments must be used in conjunction with psychotherapy.1 An officer of the TGA and the ethics committee must also satisfy themselves that “a suitably robust treatment...
Psilocybin reduces symptoms in treatment resistant depression, trial results show
British medical journal November 2, 2022 G. Iacobucci 5 citations
single a Researchers investigated the effects of single doses of 25 mg, 10 mg, or 1 mg (control) psilocybin over 12 weeks in 233 patients with treatment resistant depression. They were given the treatment in specialised rooms designed to provide a non-clinical and calming atmosphere where a specially trained therapist was available to provide psychological support. The psychedelic effects of...
Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial
British medical journal February 2, 2022 M. Abbar, C. Demattei, Wissam El-Hage et al. 172 citations
Abstract Objective To confirm the rapid onset anti-suicidal benefits of ketamine in the short term and at six weeks, overall and according to diagnostic group. Design Prospective, double blind, superiority, randomised placebo controlled trial. Setting Seven French teaching hospitals between 13 April 2015 and 12 March 2019. Eligibility criteria for participants Aged 18 or older with current...